What are the potential benefits of CGRP (Calcitonin Gene-Related Peptide)?

As target: anti-CGRP biologics prevent 50%+ of migraine days in responders. Gepant CGRP antagonists provide acute migraine abortion. Understanding CGRP enabled development of the first mechanism-specific migraine drugs. CGRP itself has vasodilatory and cardioprotective roles in ischemia. Research target for cluster headache and other trigeminovascular conditions

What compounds work synergistically with CGRP (Calcitonin Gene-Related Peptide)?

CGRP (Calcitonin Gene-Related Peptide) has been studied alongside Erenumab, Fremanezumab, Rimegepant, Ubrogepant for potential synergistic effects.

CGRP (Calcitonin Gene-Related Peptide) — Mechanism, Benefits, Research & Synergies

Overview

Calcitonin Gene-Related Peptide (CGRP) is a 37-amino acid neuropeptide produced by alternative splicing of the calcitonin gene, expressed abundantly in trigeminal sensory neurons. It is the most potent endogenous vasodilator known and plays a central role in migraine pathophysiology. CGRP itself is not used therapeutically; rather, anti-CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab) and CGRP receptor antagonists ('gepants': rimegepant, ubrogepant) targeting this peptide have revolutionized migraine prevention and acute treatment.

Mechanism of Action

CGRP binds a heterodimeric GPCR complex consisting of calcitonin receptor-like receptor (CLR) combined with receptor activity-modifying protein 1 (RAMP1). Activation stimulates adenylyl cyclase (cAMP/PKA) in vascular smooth muscle, causing potent and prolonged vasodilation. In the trigeminal system, CGRP is released from trigeminal ganglion neurons during migraine attacks, promoting neurogenic inflammation, mast cell degranulation, and sensitization of central pain pathways (central sensitization/allodynia). Blocking CGRP signaling with antibodies or small molecule antagonists interrupts this cascade.

Potential Benefits

As target: anti-CGRP biologics prevent 50%+ of migraine days in responders
Gepant CGRP antagonists provide acute migraine abortion
Understanding CGRP enabled development of the first mechanism-specific migraine drugs
CGRP itself has vasodilatory and cardioprotective roles in ischemia
Research target for cluster headache and other trigeminovascular conditions

Research Dosage Notes

The following reflects doses used in published research studies. This is not medical advice.

CGRP itself: research use only. Anti-CGRP antibodies: once-monthly subcutaneous injection (preventive). Gepants: oral acute dosing.

Amino Acid Sequence

Ala-Cys-Asp-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH2

Side Effects & Safety

CGRP itself: hypotension at pharmacological doses, flushing
Anti-CGRP antibodies: constipation, injection site reactions

Synergistic Compounds

The following compounds have been studied alongside CGRP (Calcitonin Gene-Related Peptide) for potential complementary or synergistic effects:

ErenumabFremanezumabRimegepantUbrogepant

Learn More

Beginner's GuideNew to peptides? Start here Stacking GuideSynergistic combinations Administration RoutesSubQ, IM, oral, nasal & more Reconstitution CalculatorCalculate exact dosing Peptides vs SARMsFull comparison How Peptides Are MadeSPPS, purification & QC

References & Further Reading

[object Object]
[object Object]

Quick Facts

Molecular Weight	3789.3 g/mol
Research Status	CGRP itself: extensively characterized research peptide. Anti-CGRP antibodies: FDA-approved 2018 (erenumab/Aimovig, fremanezumab/Ajovy, galcanezumab/Emgality). Gepants: FDA-approved 2019–2020.

More Peptides in This Category

BPC-157 TB-500 Selank DSIP Vasoactive Intestinal Peptide Substance P

CGRP (Calcitonin Gene-Related Peptide)